s20098 and Anxiety
s20098 has been researched along with Anxiety in 25 studies
Research
Studies (25)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| El-Khatib, YA; Khattab, MM; Sallam, NA; Sayed, RH; Zaki, HF | 1 |
| Fischer, G; Fong, G; Kherlopian, A | 1 |
| Boudah, A; Jasmin, L; Rebai, R | 1 |
| Khoo, JP; Olivier, V; Picarel-Blanchot, F; Stein, DJ; Van Ameringen, M | 1 |
| Atanasova, D; Atanasova, M; Ilieva, K; Kortenska, L; Tchekalarova, J | 2 |
| Abulsoud, AI; Fathi, D; Maksimos, MM; Nassar, NN; Rizk, SM; Saad, MA; Senousy, MA | 1 |
| Dreyer, W; Harvey, BH; Möller, M; Regenass, W | 1 |
| Kennedy, SH; Picarel-Blanchot, F; Stein, DJ | 1 |
| Bruno, A; Caminiti, M; Cogliandro, N; Lorusso, S; Micò, U; Muscatello, MR; Pandolfo, G; Zoccali, RA | 1 |
| Emtsov, KG; Panova, NB; Popova, YV; Pribytkov, AA | 1 |
| De Bodinat, C; Delagrange, P; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Munoz, C | 1 |
| Petrova, MM; Piliugina, MS; Savchenko, AA; Shimohina, NY | 1 |
| Egorov, AY | 1 |
| Antonen, EG; Kruchek, MM; Nikitina, MV | 1 |
| Corral, R; Gargoloff, PD; Gargoloff, PR; Herbst, L; Marquez, M; Martinotti, G | 1 |
| Kennedy, SH | 1 |
| Owen, RT | 1 |
| Baylé, FJ; Hajak, G; Hoogendijk, WJ; Kasper, S; Montejo, AL; Picarel-Blanchot, F; Quera-Salva, MA; Rybakowski, JK; Smeraldi, E; Wirz-Justice, AM; Wulff, K | 1 |
| Caputo, A; Fava, M; Post, A; Shah, A; Stahl, SM; Trivedi, MH | 1 |
| Green, B | 1 |
| Banasr, M; Daszuta, A; Fagioli, F; Gabriel, C; Maccari, S; Mairesse, J; McEwen, B; Mocaer, E; Morley-Fletcher, S; Nicoletti, F; Soumier, A | 1 |
| Brocco, M; Dekeyne, A; Gobert, A; Millan, MJ | 1 |
| Hamon, M; Le Bihan, C; Loiseau, F; Thiébot, MH | 1 |
| Dubocovich, ML | 1 |
Reviews
6 review(s) available for s20098 and Anxiety
| Article | Year |
|---|---|
Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
Topics: Acetamides; Anxiety; Anxiety Disorders; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Circadian Rhythm; Depression; Humans; Neurogenesis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2014 |
Treating each and every depressed patient.
Topics: Acetamides; Age Factors; Antidepressive Agents; Anxiety; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Male; Patient Selection; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Sex Factors; Sleep; Time Factors; Treatment Outcome | 2008 |
Agomelatine: a novel pharmacological approach to treating depression.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Drug Interactions; Humans; Melatonin; Secondary Prevention; Sleep Wake Disorders; Substance Withdrawal Syndrome | 2009 |
Focus on agomelatine.
Topics: Acetamides; Adult; Animals; Antidepressive Agents; Anxiety; Bipolar Disorder; Depression; Dose-Response Relationship, Drug; Humans; Hypnotics and Sedatives; Models, Biological; Sleep; Treatment Outcome | 2011 |
Agomelatine targets a range of major depressive disorder symptoms.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Circadian Rhythm; Clinical Trials as Topic; Contraindications; Depressive Disorder, Major; Drug Evaluation, Preclinical; Humans; Receptors, Melatonin; Receptors, Serotonin; Sleep; Sleep Initiation and Maintenance Disorders; Structure-Activity Relationship | 2006 |
Trials
7 trial(s) available for s20098 and Anxiety
| Article | Year |
|---|---|
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Melatonin; Middle Aged; Treatment Outcome | 2013 |
Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study.
Topics: Acetamides; Affect; Analgesics; Antidepressive Agents; Anxiety; Chronic Pain; Cognition; Depression; Executive Function; Female; Fibromyalgia; Humans; Middle Aged; Neuropsychological Tests; Pain Measurement; Pilot Projects; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2013 |
[Efficacy of agomelatine in depressive disorders with anxiety].
Topics: Acetamides; Adult; Aged; Anxiety; Depressive Disorder; Female; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
[The use of agomelatine (valdoxan) in gambling therapy: a pilot study].
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Female; Gambling; Humans; International Classification of Diseases; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Young Adult | 2015 |
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.
Topics: Acetamides; Adult; Aged; Ambulatory Care; Anhedonia; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Remission Induction; Severity of Illness Index; Treatment Outcome | 2016 |
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Topics: Acetamides; Actigraphy; Adolescent; Adult; Antidepressive Agents; Anxiety; Circadian Rhythm; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Motor Activity; Psychiatric Status Rating Scales; Rest; Sertraline; Severity of Illness Index; Sleep; Treatment Outcome | 2010 |
Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Quality of Life; Sleep; Surveys and Questionnaires; Treatment Outcome | 2010 |
Other Studies
12 other study(ies) available for s20098 and Anxiety
| Article | Year |
|---|---|
17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats.
Topics: Acetamides; Animals; Anxiety; Depression; Drug Synergism; Estradiol; Female; Hypnotics and Sedatives; Neuroprotective Agents; Ovariectomy; Rats; Rats, Wistar; Swimming | 2020 |
Drug reaction with eosinophilia and systemic symptoms due to agomelatine.
Topics: Acetamides; Anxiety; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Female; Humans; Hypnotics and Sedatives; Middle Aged | 2021 |
Agomelatine effects on fat-enriched diet induced neuroinflammation and depression-like behavior in rats.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Depression; Diet, High-Fat; Disease Models, Animal; Inflammation; Inflammation Mediators; Male; Oxidative Stress; Rats, Wistar | 2021 |
Chronic agomelatine treatment alleviates icvAβ-induced anxiety and depressive-like behavior through affecting Aβ metabolism in the hippocampus in a rat model of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anxiety; Disease Models, Animal; Hippocampus; Rats | 2021 |
Agomelatine attenuates alcohol craving and withdrawal symptoms by modulating the Notch1 signaling pathway in rats.
Topics: Acetamides; Alcoholic Beverages; Animals; Anxiety; Behavior, Animal; Biomarkers; Circadian Rhythm; Craving; Hippocampus; Hydrocortisone; Male; Morris Water Maze Test; Neuronal Plasticity; Neurons; Neurotransmitter Agents; Open Field Test; Period Circadian Proteins; Rats, Wistar; Receptor, Notch1; Signal Transduction; Substance Withdrawal Syndrome | 2021 |
Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Topics: Acetamides; Alzheimer Disease; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Disease Models, Animal; Exploratory Behavior; Hippocampus; Male; Maze Learning; Melatonin; Memory Disorders; Rats; Rats, Sprague-Dawley; Streptozocin | 2019 |
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Corticosterone; Female; Male; Oxytocin; Rats; Rats, Sprague-Dawley; Social Isolation; Vasopressins | 2019 |
[An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders].
Topics: Acetamides; Acute Coronary Syndrome; Adult; Aged; Anxiety; Central Nervous System Depressants; Depressive Disorder; Dose-Response Relationship, Drug; Female; Hemostasis; Humans; Male; Melatonin; Middle Aged; Treatment Outcome | 2015 |
[Clinical experience of the use of agomelatine in the treatment of patients with depression and chronic brain ischemia].
Topics: Acetamides; Adult; Anxiety; Brain Ischemia; Chronic Disease; Depression; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Sleep; Sleep Initiation and Maintenance Disorders | 2015 |
Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cell Proliferation; CREB-Binding Protein; Data Interpretation, Statistical; Depression; Female; Hippocampus; Immunoblotting; Male; Maze Learning; Neurogenesis; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Stress, Psychological | 2011 |
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Chemistry; Clorazepate Dipotassium; Conflict, Psychological; Dose-Response Relationship, Drug; Hippocampus; Indoles; Interpersonal Relations; Male; Melatonin; Mice; Microdialysis; Motor Activity; Norepinephrine; Pyridines; Rats; Receptor, Serotonin, 5-HT2C; Receptors, GABA-A; Serotonin; Serotonin Antagonists; Synaptic Transmission; Thiophenes; Vocalization, Animal | 2005 |
Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam.
Topics: Acetamides; Animals; Anxiety; Conditioning, Operant; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Male; Melatonin; Motor Activity; Rats; Rats, Wistar | 2006 |